Given the evidence of some synergy in the growth inhibition of the TSC1/TSC2 null cell lines in response to combined mTOR and HSP90 inhibition, and evidence that they were impacting growth through different mechanisms, we explored the potential synergistic effect of treatment with these compounds in vivo using a subcutaneous xenograft tumor model with SNU-398 cells. This evidence concerns the gene TSC1 and neoplasm.